UK population based study to predict impact of HPV vaccination

作者：Hibbitts Sam^*; Tristram Amanda; Beer Helen; McRea Jane; Rose Bryan; Hauke Anne; Nuttall Dave; Dallimore Nick; Newcombe Robert G; Fiander Alison

来源：Journal of Clinical Virology, 2014, 59(2): 109-114.

DOI：10.1016/j.jcv.2013.12.002

• Human papillomavirus (HPV)
• Cervical screening
• HPV vaccination
• Cervarix and Gardasil

Background: In 2008 a human papillomavirus (HPV) vaccination programme for cervical cancer prevention was implemented in the UK. Surveillance of vaccine uptake, impact on prevalence of HPV infection and cervical cancer incidence were identified as key measures to evaluate the intervention.
Objective: To determine baseline HPV prevalence in unvaccinated women and predict impact of HPV vaccination on high-grade cervical disease (CIN2+).
Study design: A pseudo-anonymous prospective cohort was sampled on entry to the routine cervical screening programme between March 2009 and November 2010. In total, 13,306 eligible females were identified and high-risk (hrHPV) type specific status determined. Potential impact of prophylactic vaccination on CIN2+ was calculated by applying HPV vaccine clinical trial data to the baseline HPV type-specific data.
Results: Of 13,306 samples tested, 3545 (26.6%) were confirmed positive for at least one hrHPV type and 1325(10%) were positive for low risk HPV. HPV16 was the predominant type detected in cases positive with either single or multiple hrHPV infection(s) (5.2% and 4.7%, respectively). Based on hrHPV typespecific data, Gardasil would have prevented 33.2% HPV16/18 unrelated CIN2+ compared to 47.1% for Cervarix. This difference was not statistically significant.
Conclusion: Prior to the introduction of the HPV vaccine, approximately one-quarter of young women were positive for hrHPV and one-tenth positive for HPV16. Post-vaccination, we anticipate a substantial absolute risk reduction in high-grade cervical disease associated with both targeted and non-targeted hrHPV types. There is no significant difference between the two commercially available vaccines in terms of clinical impact.

• 出版日期2014-2